Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus LYNOZYFIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus LYNOZYFIC.
KERYDIN vs LYNOZYFIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin transporter (SERT) in the presynaptic terminal, increasing synaptic serotonin levels.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
1000 mg intravenously every 12 hours infused over 2 hours
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life is 12.4 hours (range 11.2–14.1 hours) in patients with normal renal function; allows twice-daily dosing for steady-state within 3 days.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion accounts for 25%; the remaining 10% is metabolized by hepatic CYP3A4-mediated oxidation.
Category C
Category C
Antifungal
Antifungal